- $549.60m
- $477.60m
Brief: Oculis Announces Completion Of Oversubscribed $59 Mln Registered Direct Offering
Brief: Oculis Holding Initiated Second Phase 3 Optimize-2 Trial With Ocs-01 Once Daily Eye Drop In Late 2023 & Topline Readout Expected Before End Of 2024
Brief: Oculis Holding AG Files For Mixed Shelf Offering Of Up To $300 mln
Brief: Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
Brief: Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01
Brief: Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema
Brief: Oculis Announces First Patient First Visit In Phase 2B Relief Trial Of Dry Eye Disease Drug
Brief: Oculis Holding Shows Positive Phase 3, Stage 1 Diamond Trial Results Of Ocs-01 In Diabetic Macular Edema
Brief: Oculis Holding Says OCS-01 Eye Drop Met Both Primary Endpoints In Phase 3 Optimize Trial
Oculis up after eye drug meets main goal in late-stage study
Oculis' eye drug meets main goal in study (updated)
Oculis' eye drug meets main goal in study
Brief: Oculis SA And European Biotech Acquisition Corp Announce Business Combination Agreement To Create Nasdaq-Listed Biopharmaceutical Company